Related Experiment Video
Updated: May 30, 2026
An Electrochemiluminescence-Based Assay for MeCP2 Protein Variants
Published on: May 22, 2020
Clonal Rett Syndrome cell lines to test compounds for activation of wild-type MeCP2 expression
Dongbo Yu1, Fuminori Sakurai, David R Corey
1Department of Pharmacology, UT Southwestern Medical Center at Dallas, Dallas, 6001 Forest Park Road, TX 75390, USA.
Abstract:
Rett Syndrome is an X-linked progressive neurological disorder caused by inactivation of one allele of the MECP2 gene. There are no curative treatments, and activation of wild-type MECP2 expression is one strategy for stabilizing or reversing the disease. We isolated fibroblast clones that express exclusively either the wild-type or a 32-bp-deletion mutant form of MECP2. We developed a sensitive assay for measuring wild-type MECP2 mRNA levels and tested small molecule epigenetic activators for their ability to activate gene expression. Although our pilot screen did not identify activators of MECP2 expression, it established the value of using clonal cells and defined challenges that must be overcome.
Insights
Researchers explored activating the MECP2 gene to treat Rett Syndrome, a neurological disorder. While this pilot study did not find gene activators, it validated a method for future drug discovery.
Area of Science:
- Neuroscience
- Genetics
- Molecular Biology
Background:
- Rett Syndrome is a progressive neurological disorder linked to the MECP2 gene.
- Current treatments for Rett Syndrome are limited, highlighting the need for novel therapeutic strategies.
- Activating wild-type MECP2 gene expression is a potential approach for disease stabilization or reversal.
Purpose of the Study:
- To investigate small molecule epigenetic activators for their potential to increase wild-type MECP2 gene expression.
- To establish a reliable method for measuring MECP2 mRNA levels in clonal cell lines.
Main Methods:
- Fibroblast clones expressing either wild-type or mutant MECP2 were isolated.
- A sensitive assay was developed to quantify wild-type MECP2 mRNA levels.
- A pilot screen of small molecule epigenetic activators was conducted.
Main Results:
- The pilot screen did not identify any small molecules that activated MECP2 expression.
- The study successfully established the utility of using clonal cell lines for this research.
- Key challenges for future MECP2 activation studies were defined.
Conclusions:
- While no MECP2 activators were found in this initial screen, the methodology is promising for future research.
- The use of clonal fibroblast lines is a valuable approach for studying MECP2 gene activation.
- Further research is needed to overcome challenges and identify effective therapeutic strategies for Rett Syndrome.
